NASHVILLE, Tenn.—
Harrow, a U.S. eyecare pharmaceutical company, (Nasdaq: HROW) has announced its results for the first quarter ended March 31, 2024. In the first quarter of 2024, Harrow recorded revenues of $34.6 million, a 33 percent increase over the $26.1 million realized in the prior-year quarter.
Read more...